Stay updated with breaking news from I Mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
I-Mab (NASDAQ:IMAB – Get Rating) is set to announce its earnings results before the market opens on Friday, March 31st. Investors interested in listening to the company’s conference call can do so using this link. I-Mab Stock Performance Shares of NASDAQ:IMAB opened at $3.14 on Wednesday. I-Mab has a 52-week low of $2.73 and a […]
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
/PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and...